| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Goat |
| Applications | ELISA,WB-Ti |
| Brand: | Abnova |
| Reference: | PAB6114 |
| Product name: | DUSP8 polyclonal antibody |
| Product description: | Goat polyclonal antibody raised against synthetic peptide of DUSP8. |
| Gene id: | 1850 |
| Gene name: | DUSP8 |
| Gene alias: | C11orf81|FLJ42476|FLJ42958|HB5|HVH-5|HVH8 |
| Gene description: | dual specificity phosphatase 8 |
| Immunogen: | A synthetic peptide corresponding to human DUSP8. |
| Immunogen sequence/protein sequence: | *AGDRLPRKVMDAK-C |
| Protein accession: | NP_004411.1 |
| Form: | Liquid |
| Concentration: | 0.5 mg/mL |
| Recommend dilutions: | ELISA (1:4000) Western blot (1-3 ug/mL) The optimal working dilution should be determined by the end user. |
| Storage buffer: | In Tris saline, pH 7.3 (0.5% BSA, 0.02% sodium azide) |
| Storage instruction: | Store at -20°C. Aliquot to avoid repeated freezing and thawing. |
| Quality control testing: | Antibody Reactive Against Synthetic Peptide. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Goat |
| Antigen species / target species: | Human |
| Specificity: | This antibody is also expected to recognize the hypothetical human protein similar to dual specificity phosphatase 8 (XM_114902), which is virtually identical. |
| Reactivity: | Human |
| Application image: | ![]() |
| Application image note: | DUSP8 polyclonal antibody (Cat # PAB6114) staining (2 ug/mL) of human heart lysate (RIPA buffer, 30 ug total protein per lane). Primary incubated for 12 hour. Detected by western blot using chemiluminescence. |
| Applications: | ELISA,WB-Ti |
| Shipping condition: | Dry Ice |
| Publications: | hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase.Martell KJ, Seasholtz AF, Kwak SP, Clemens KK, Dixon JE. J Neurochem. 1995 Oct;65(4):1823-33. |